chalkrod76

About

A multicentre randomised cycle 3 demo evaluating pembrolizumab as opposed to single-agent radiation with regard to innovative pre-treated malignant pleural mesothelioma: the ecu Thoracic Oncology Podium (ETOP 9-15) PROMISE-meso test.